Nova Eye Medical Ltd

As of June 30, 2025, Nova Eye Medical Ltd carries a market capitalization of 31.32M, placing it among publicly traded companies globally. Its enterprise value stands at 29.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nova Eye Medical Ltd's next confirmed earnings release is scheduled for March 2, 2027.

As of June 30, 2025, Nova Eye Medical Ltd has 284.71M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 0.93, and the price-to-book ratio stands at 1.65.

These figures are as of June 30, 2025. The EV/Sales ratio of 1.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 29.28M versus a market cap of 31.32M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Nova Eye Medical Ltd maintains a current ratio of 2.39, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Nova Eye Medical Ltd posted a negative return on equity (ROE) of -44.96, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -32.13, reflecting losses generated across the asset base. Inventory turnover of 2.59 indicates how many times Nova Eye Medical Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Nova Eye Medical Ltd's stock has declined approximately 3.13% over the past 52 weeks. The 50-day moving average sits at 0.14, while the 200-day moving average is 0.14.

Over the twelve months ended June 30, 2025, Nova Eye Medical Ltd generated 29.27M in revenue and converted that into -9.06M in net income, yielding earnings per share of -0.04. EBITDA reached -8.98M, while operating income came in at -11.25M.

As of June 30, 2025, Nova Eye Medical Ltd holds 5.06M in cash and equivalents against 3.02M in total debt, resulting in a net debt position of -5.05M. Total book value stands at 18.97M, with working capital of 7.17M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Nova Eye Medical Ltd posted a gross margin of 68.56, reflecting its pricing power and cost economics. The operating margin of -38.43 and net profit margin of -30.95 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -17.74, meaning Nova Eye Medical Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Nova Eye Medical Ltd's most recent stock split took place on February 14, 2024 with a 482:495 split ratio.

As of June 30, 2025, Nova Eye Medical Ltd has an Altman Z-Score of -0.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.